Author's response to reviews

Title: Expressions of HIF-1alpha and VEGF in colorectal cancer: correlations with clinical outcomes and prognostic implications

Authors:

Dan Cao (caodan316@163.com)
Mei Hou (caodan316@163.com)
Jiang Ming (mingminyu@gmail.com)
Yang Yu (yangyuflying@hotmail.com)
Feng Hong Gou (joan.gou@gmail.com)

Version: 2 Date: 18 March 2009

Author's response to reviews: see over
Dear editors:

Here is a manuscript by Dan Cao, Mei Hou, Jiang Ming, Yang Yu, Hongfeng Gou entitled “Expressions of HIF-1alpha and VEGF in colorectal cancer: correlation with clinical outcomes and prognostic implications”. It’s submitted to be considered for publication oncology as a research article. This paper is new, neither the entire paper nor any part of its content has been published or has been accepted elsewhere. It is not being submitted to any other journal. The manuscript was revised by a scholar of medical English for grammar.

We believe this research may be of particular interest to the readers of your journal. Although HIF-1α and VEGF were reported to be expressed in many types of cancers, no data regarding their correlations with clinical outcomes and prognostic implications, in particular, in human colorectal cancer, have yet been reported. Our results suggest that HIF-1 alpha could be a marker of tumor infiltration evaluation and poor prognosis in colorectal cancer and as a future perspective, biological agents targeting HIF1- alpha and VEGF might be more effective at CRC, which has the potential to improve outcomes.

All authors have given their approval for the submission of the paper.

Correspondence and phone calls about the paper should be directed to Dr. Mei Hou at the following address, phone, and e-mail address:

Dr. Mei Hou:

Division of thoracic cancer, West China Hospital, Guo Xue Xiang No.37, City of Cheng Du, Si Chuan, China. 610041

E-mail address: caodan316@163.com

Phone numbers: +86-028-85423609

Fax numbers: +86-028-85423609

Details of my revisions:

I have revised my manuscript to include the statement of ethical approval and informed consent for this study in the Methods section. The present study involving the human tissue samples was approved by the medical ethics committee of West China Hospital of Sichuan University. Informed consents from patients were obtained for the use of resected tumor specimens.